ESTRO 2024 - Abstract Book

S1825

Clinical - Lung

ESTRO 2024

Conclusion:

Administering single-dose stereotactic RT appears viable for specific lung tumor patients. A higher dosage correlated with enhanced local control. Extended observation is essential to fully gauge the treatment's effectiveness and associated side effects.

Kerem

Keywords: SBRT, Single Fraction, SABR

3232

Proffered Paper

Five-Year survival and safety outcomes from the START-NEW-ERA non-randomised phase II trial

Fabio Arcidiacono 1 , Paola Anselmo 1 , Michelina Casale 1 , Cristina Zannori 2 , Fabio Loreti 3 , Benedetta Enrico 4 , Valentina Tassi 5 , Marco Italiani 1 , Ernesto Maranzano 1 , Fabio TRIPPA 1 1 Radiotherapy Oncology Centre "S.Maria" Hospital, Oncology, Terni, Italy. 2 Medical Oncology, Oncology, Terni, Italy. 3 Nuclear Medicine Service, Oncology, Terni, Italy. 4 Radiology Service, Oncology, Terni, Italy. 5 Thoracic Surgery Division, Oncology, Terni, Italy

Purpose/Objective: